What is a stock summary page? Click here for an overview.
Business Description
Pacira BioSciences Inc
NAICS : 325412
SIC : 2834
ISIN : US6951271005
Compare
Compare
Traded in other countries / regions
PCRX.USA82P.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2011-02-03Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.76 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.82 | |||||
| Debt-to-EBITDA | 21.94 | |||||
| Interest Coverage | 7.26 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.35 | |||||
| Beneish M-Score | -2.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.5 | |||||
| 3-Year EBITDA Growth Rate | -36.8 | |||||
| 3-Year EPS without NRI Growth Rate | 25.5 | |||||
| 3-Year FCF Growth Rate | 30.2 | |||||
| 3-Year Book Growth Rate | 1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.82 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.02 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.55 | |||||
| 9-Day RSI | 61.86 | |||||
| 14-Day RSI | 56.81 | |||||
| 3-1 Month Momentum % | 29.69 | |||||
| 6-1 Month Momentum % | 77.07 | |||||
| 12-1 Month Momentum % | -11.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | |||||
| Quick Ratio | 2 | |||||
| Cash Ratio | 1.56 | |||||
| Days Inventory | 232.04 | |||||
| Days Sales Outstanding | 54.77 | |||||
| Days Payable | 35.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | 0.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.69 | |||||
| Operating Margin % | 13.92 | |||||
| Net Margin % | -14.2 | |||||
| FCF Margin % | 25.5 | |||||
| ROE % | -11.94 | |||||
| ROA % | -6.32 | |||||
| ROIC % | 13.58 | |||||
| 3-Year ROIIC % | -9.34 | |||||
| ROC (Joel Greenblatt) % | -13.3 | |||||
| ROCE % | -3.56 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.79 | |||||
| PE Ratio without NRI | 16.56 | |||||
| Shiller PE Ratio | 248.4 | |||||
| PEG Ratio | 3.68 | |||||
| PS Ratio | 1.65 | |||||
| PB Ratio | 1.48 | |||||
| Price-to-Tangible-Book | 3.26 | |||||
| Price-to-Free-Cash-Flow | 6.83 | |||||
| Price-to-Operating-Cash-Flow | 6.5 | |||||
| EV-to-EBIT | -25.62 | |||||
| EV-to-EBITDA | 43.69 | |||||
| EV-to-Revenue | 1.82 | |||||
| EV-to-Forward-Revenue | 1.68 | |||||
| EV-to-FCF | 7.03 | |||||
| Price-to-GF-Value | 0.65 | |||||
| Price-to-Projected-FCF | 0.67 | |||||
| Price-to-Median-PS-Value | 0.34 | |||||
| Price-to-Graham-Number | 1.55 | |||||
| Earnings Yield (Greenblatt) % | -3.9 | |||||
| FCF Yield % | 15.55 | |||||
| Forward Rate of Return (Yacktman) % | 10.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pacira BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 700.966 | ||
| EPS (TTM) ($) | -2.19 | ||
| Beta | 0.54 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.84 | ||
| Volatility % | 63.25 | ||
| 14-Day RSI | 56.81 | ||
| 14-Day ATR ($) | 1.057268 | ||
| 20-Day SMA ($) | 23.759 | ||
| 12-1 Month Momentum % | -11.93 | ||
| 52-Week Range ($) | 11.164 - 31.67 | ||
| Shares Outstanding (Mil) | 46.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pacira BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pacira BioSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pacira BioSciences Inc Frequently Asked Questions
What is Pacira BioSciences Inc(PCRX)'s stock price today?
The current price of PCRX is $24.84. The 52 week high of PCRX is $31.67 and 52 week low is $11.16.
When is next earnings date of Pacira BioSciences Inc(PCRX)?
The next earnings date of Pacira BioSciences Inc(PCRX) is 2025-05-07 Est..
Does Pacira BioSciences Inc(PCRX) pay dividends? If so, how much?
Pacira BioSciences Inc(PCRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers